Related references
Note: Only part of the references are listed.Negative impact of anorexia and weight loss during prior pirfenidone administration on subsequent nintedanib treatment in patients with idiopathic pulmonary fibrosis
Satoshi Ikeda et al.
BMC PULMONARY MEDICINE (2019)
Diagnosis of Idiopathic Pulmonary Fibrosis An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
Ganesh Raghu et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2018)
Significance of molecular biomarkers in idiopathic pulmonary fibrosis: A mini review
Hirofumi Chiba et al.
RESPIRATORY INVESTIGATION (2018)
Therapeutic targets in idiopathic pulmonary fibrosis
Martin Kolb et al.
RESPIRATORY MEDICINE (2017)
Serum surfactant protein D predicts the outcome of patients with idiopathic pulmonary fibrosis treated with pirfenidone
Kimiyuki Ikeda et al.
RESPIRATORY MEDICINE (2017)
Prognostic value of serial serum KL-6 measurements in patients with idiopathic pulmonary fibrosis
Kentaro Wakamatsu et al.
RESPIRATORY INVESTIGATION (2017)
Nintedanib and Pirfenidone New Antifibrotic Treatments Indicated for Idiopathic Pulmonary Fibrosis Offer Hopes and Raises Questions
Ganesh Raghu et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2015)
An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis An Update of the 2011 Clinical Practice Guideline
Ganesh Raghu et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2015)
Epidemiologic Survey of Japanese Patients with Idiopathic Pulmonary Fibrosis and Investigation of Ethnic Differences
Motoki Natsuizaka et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2014)
A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Talmadge E. King et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Luca Richeldi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Distinct compartmentalization of SP-A and SP-D in the vasculature and lungs of patients with idiopathic pulmonary fibrosis
Hirotaka Nishikiori et al.
BMC PULMONARY MEDICINE (2014)
An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias
William D. Travis et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2013)
Safety and efficacy of pirfenidone in idiopathic pulmonary fibrosis in clinical practice
Ryo Okuda et al.
RESPIRATORY MEDICINE (2013)
Biomarkers in idiopathic pulmonary fibrosis
Yingze Zhang et al.
CURRENT OPINION IN PULMONARY MEDICINE (2012)
Forced Vital Capacity in Patients with Idiopathic Pulmonary Fibrosis Test Properties and Minimal Clinically Important Difference
Roland M. du Bois et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2011)
An Official ATS/ERSARS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management
Ganesh Raghu et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2011)
Long-term Course and Prognosis of Idiopathic Pulmonary Fibrosis in the New Millennium
Steven D. Nathan et al.
CHEST (2011)
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Paul W. Noble et al.
LANCET (2011)
Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis
C. J. Zappala et al.
EUROPEAN RESPIRATORY JOURNAL (2010)
Serum Surfactant Protein-A Is a Strong Predictor of Early Mortality in Idiopathic Pulmonary Fibrosis
Brent W. Kinder et al.
CHEST (2009)
Antifibrotic action of pirfenidone and prednisolone: Different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis
Hisashi Oku et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2008)
Increased levels of KL-6 and subsequent mortality in patients with interstitial lung diseases
H. Satoh et al.
JOURNAL OF INTERNAL MEDICINE (2006)
Prognostic value of circulating KL-6 in idiopathic pulmonary fibrosis
A Yokoyama et al.
RESPIROLOGY (2006)
Pulmonary surfactant proteins A and D: Innate immune functions and biomarkers for lung diseases
H Takahashi et al.
CURRENT PHARMACEUTICAL DESIGN (2006)
Monitoring markers of disease activity for interstitial lung diseases with serum surfactant proteins A and D
H Takahashi et al.
RESPIROLOGY (2006)
Serum surfactant proteins A and D as prognostic factors in idiopathic pulmonary fibrosis and their relationship to disease extent
H Takahashi et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2000)
Share Paper
